Unibest

Pharmaceutical intermediates

Avapritinib Intermediates

2 pharmaceutical intermediates for Avapritinib. Indication: Systemic Mastocytosis; Gastrointestinal Stromal Tumor (GIST); Mast Cell Leukemia.

提交项目All intermediates

About Avapritinib

Originator
Blueprint Medicines Corp
Indication
Systemic Mastocytosis; Gastrointestinal Stromal Tumor (GIST); Mast Cell Leukemia
Approved Date
06/16/2021
NCE Patent
01/09/2025
DS/DP
10/15/2034

Available intermediates

2 intermediates currently listed for Avapritinib. Request specifications, documentation or a quotation for any item below.

Avapritinib intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
Ethyl 2-chloropyrimidine-5-carboxylate89793-12-4//
1-Methyl-4-pyrazole boronic acid pinacol ester761446-44-0//

Other programs under A

AbemaciclibAbrocitinibAcalabrutinibAdagrasibAfatinibAfoxolanerAlectinib HydrochlorideAlfacalcidol

Building toward Avapritinib?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →